In a BRAF-mutated model of mouse melanoma, the BRAF-inhibitor PLX4720 selectively decreased the number of CD4+Foxp3+ Treg cells and of CD11b+Gr1+ myeloid-derived suppressor cells (MDSC) in the tumor microenvironment. Here, CD4 is linked to melanoma.